Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Stock picking requires research and discipline; assess whether your time, resources, and goals justify active selection over passive options.
17,093 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Goldman Sachs and JPMorgan cut targets on Kohl’s as consumer demand cools, signaling a tougher 2026. The moves come a...
Hims & Hers Health shifts to selling branded Wegovy and Ozempic after a settlement with Novo Nordisk, reversing regul...
Nvidia has reportedly extended a new funding round for Nebius, expanding its footprint in AI infrastructure. Analysts...
A colossal AI infrastructure agreement links Meta Platforms with Nebius in a five-year plan worth $27 billion. This a...
Netflix charts a high-stakes path, slowing buybacks to fund a debt-heavy growth plan and weighing a marquee deal, as ...
Wall Street predicts these three AI stocks could double within four years as demand for AI infrastructure and memory ...
SanDisk announced a $1 billion strategic equity investment in Nanya Technology, prompting a roughly 6% share decline ...
Casey’s General Stores posted stronger fuel margins and a growing Rewards base, lifting investor optimism. Analysts c...
Strategy reported a $12.54 billion Q1 loss driven by unrealized BTC declines, even as its software business expanded ...
IGIC's Q1 2026 results highlight growth momentum alongside margin pressure. This article breaks down the igic 2026 ea...
Amazon's liquidity position is tightening as it pours billions into AI infrastructure. Investors pore over cash metri...